SLC5A2 and heart failure: These data are consistent with the results of large, randomized controlled trials with SGLT-2 inhibitors in stable outpatients [8,9,10], and a recent study of empaglifozin in hospitalized patients admitted for heart failure also shows that empagliflozin was safe and well tolerated with less adverse events than placebo without more frequent worsening of renal function or renal adverse events [25].